CHCWM – Cancer & Hematology Centers of West Michigan

HM06-19-26 (Helsinn)

Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET gene abnormalities.